Amgen posts top-line results for Remicade alternative in Phase 3 trial

Amgen (AMGN) announced positive top-line results from the phase 3 trial of its biosimilar candidate ABP 710. The drug is a biosimilar of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab). If the drug succeeds, Amgen is well positioned to be a key player in the autoimmune biosimilars market.

https://news.alphastreet.com/amgen-posts-top-line-results-for-remicade-alternative-in-phase-3-trial/